Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Suspended NCT06639958

A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home

Conditions: Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia

Sex: All
Ages: 10 Years – 25 Years
Healthy volunteers: No
Phase: NA
Enrollment: 64
Sponsor: Children's Oncology Group

Location: Children's Hospital of Alabama Birmingham Alabama

Summary

This clinical trial tests different programs to help patients with acute lymphoblastic leukemia (ALL) remember to take their medications during maintenance therapy at home. One problem with ALL maintenance treatment is remembering to take medicines at home like patients are supposed to. In maintenance, a medicine called 6-mercaptopurine or "6MP" is taken by mouth every day at home. In this study, 6MP prescriptions are filled into a special medication bottle called MEMS® which is fitted with a special cap called TrackCap™ that electronically records when the medication bottle is opened. Researchers are trying a new program to help patients be better at taking their 6MP like they're supposed to. This new program may help patients to remember to take their 6MP medication.

Eligibility Criteria

Inclusion Criteria: * Age: \>= 10 years and =\< 25 years * Previously enrolled onto AALL1732 * Consented to the AALL1732 mercaptopurine adherence correlative study * Maintenance therapy has not yet begun * English or Spanish-speaking (patient and parent/other adult) * Planning to receive 6MP (as tablets) during maintenance phase of therapy * Able and willing to use the MEMS® TrackCap™ (e.g., not using a pillbox or prescribed liquid 6MP) * Has a designated parent/other adult who is willing to enter into a mutual agreement with the patient to participate in a daily supervised medication administration routine * Patient/parent/other adult must be willing to use a smartphone to receive medication reminders * Receiving treatment at a Children's Oncology Group (COG) institution in the United States Exclusion Criteria: * Patients who have previously participated in or are currently participating in another intervention clinical trial designed to improve adherence * Regulatory requirements * All patients and/or their parents or legal guardians must sign a written informed consent * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06639958). StuddyBuddy aggregates publicly available trial information.